OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

Q2 revenue of $29.2 million, increased 55% year-over-yearQ2 gross profit increased 59% year-over-year to $18.6 millionPaid down $4.5 million of principal on outstanding term loan during Q2Increased full year 2025 guidance to a revenue range between $104 million and $108 million and adjusted EBITDA range between $14.5 million and $17.5 million WALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended June 30, 2025. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the second quarter of 2025 increased 55% to $29.2 million, as compared to $18.8 million in the same year ago periodGross profit in the second quarter of 2025 increased 59% year-over-year to $18.6 million, from $11.7 million during the second quarter of 2024GAAP net income totaled $1.5 million or $0.08 per basic and diluted share in the second quarter of 2025, as compared to GAAP net loss of $(4.0) million or $(0.22) per basic and diluted share during the second quarter of 2024Non-GAAP net income in the second quarter totaled $4.5 million, or $0.24 per diluted share, as compared to non-GAAP net income of $0.3 million or $0.02 per diluted share during the second quarter of 2024 (see *Non-GAAP Measures below)Adjusted EBITDA for the second quarter of 2025 increased to $5.8 million compared to $0.5 million in the same year ago period (see *Non-GAAP Measures below)Cash, cash equivalents and short-term investments totaled $16.6 million as of June 30, 2025, as compared to $13.4 million as of December 31, 2024 Stephen L. Silvestro, OptimizeRx CEO, commented, “Our year-to-date results continue to deliver profitable growth ahead of expectations. Contracted revenue is now up more than 30% year-over-year, positioning us for a strong finish to the second half. We believe this momentum is a direct result of our disciplined focus on operational excellence, our relentless commitment to delivering exceptional customer experiences, our utilization of a market-leading patient finding AI technology, and our deepening partnerships across the ecosystem—all of which are contributing to meaningful, long-term shareholder value. “As our second quarter results clearly highlight, we are well on our way to becoming a Rule of 40 company. Given our strong performance and positive outlook, I’m pleased to announce that we are raising our full-year guidance. “Finally, I'm proud to say we paid down $4.5 million of principal on our outstanding term loan during the second quarter which was $4.0 million above our debt payment schedule. At this time, given the free cash flow we’re seeing being generated in our business, we intend on paying down our debt at an accelerated rate.” Rolling Twelve Months EndedJune 30,Key Performance Indicators (KPIs)**2025 2024 (in thousands, except percentages)Average revenue per top 20 pharmaceutical manufacturer$3,082 $2,753 Percent of total revenue attributable to top 20 pharmaceutical manufacturers 59% 66%Net revenue retention 121% 124%Revenue per average full-time employee$767 $658 2025 Financial Outlook The Company is increasing its 2025 guidance and expects revenue to be between $104 million and $108 million with Adjusted EBITDA to be between $14.5 million and $17.5 million. Conference Call Date:Thursday, August 7, 2025Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Toll Free:1-844-825-9789International:1-412-317-5180Conference ID:10200608Call Me:https://callme.viavid.com/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNg==Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1724635&tp_key=65e098620cCall Me Passcode:6438012Webcast Replay:The archived webcast will be on the investor relations section of the OptimizeRx website. Individual Meeting Invitation In an effort to increase relations with institutional investors, OptimizeRx management has dedicated time to hosting individual meetings with portfolio managers and analysts. If you are interested in scheduling a meeting with OptimizeRx management, please contact: adsilva@optimizerx.com or shalper@lifesciadvisors.com. *Non-GAAP Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. The reasons why we believe these measures provide useful information to investors and, for historical periods, a reconciliation of these measures to the most directly comparable GAAP measures are included in the supplemental tables that follow. Although the Company provides guidance for Adjusted EBITDA, a non-GAAP financial measure, it is not able to provide guidance to the most directly comparable GAAP measure. Reconciliations for forward-looking figures would require unreasonable effort at this time because of the uncertainty and variability of the nature and amount of certain components of various necessary GAAP components, including, for example, those related to compensation, acquisition expenses, other income, amortization or others that may arise during the year, and the Company’s management believes such reconciliations would imply a degree of precision that would be confusing or misleading to investors. For the same reasons, the Company is unable to address the probable significance of the unavailable information. **Definition of Key Performance Indicators Top 20 pharmaceutical manufacturers: We have updated the definition of “top 20 pharmaceutical manufacturers” in our key performance indicators to be based upon Fierce Pharma’s most updated list of “The top 20 pharma companies by 2024 revenue”. We previously used “The top 20 pharma companies by 2023 revenue”. As a result of this change, prior periods have been restated for comparative purposes. Net revenue retention: Net revenue retention is a comparison of revenue generated from all clients in the previous period to total revenue generated from the same clients in the following year (i.e., excludes new client relationships for the most recent year). Revenue per average full-time employee: We define revenue per average full-time employee (FTE) as total revenue over the last 12 months (LTM) divided by the average number of employees over the LTM, which is calculated by taking our total number of FTEs at the end of the prior year period by our total FTE headcount at the end of the most recent period. About OptimizeRx OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes. Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all. For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com. Important Cautions Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s future performance, expected revenues, expected Adjusted EBITDA, plans to grow shareholder value creation, plans to continue the Company’s growth and transformation, plans to position the Company to become a “Rule of 40” company, plans to pay down debt at an accelerated rate, and other statements relating to future performance, plans, and expectations. These forward-looking statements are based on the Company’s current expectations and involve assumptions regarding the Company’s business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, its subsequent Quarterly Reports on Form 10-Q, and in other filings the Company has made and may make with the Securities and Exchange Commission in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. OptimizeRx ContactAndy D’Silva, SVP Corporate Financeadsilva@optimizerx.com Investor Relations ContactSteven HalperLifeSci Advisors, LLCshalper@lifesciadvisors.com OPTIMIZERX CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) June 30,2025 December 31,2024ASSETS(unaudited) Current assets Cash and cash equivalents$16,585 $13,380 Accounts receivable, net of allowance for credit losses of $260 and $335 at June 30, 2025 and December 31, 2024, respectively 33,512 38,212 Taxes receivable 646 — Prepaid expenses and other assets 3,337 2,379 Total current assets 54,080 53,971 Property and equipment, net 134 150 Other assets Goodwill 70,869 70,869 Patent rights, net 5,181 5,517 Technology assets, net 7,677 8,180 Tradename and customer relationships, net 30,634 31,819 Operating lease right of use assets 528 366 Security deposits and other assets 162 296 Total other assets 115,051 117,047 TOTAL ASSETS$169,265 $171,168 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Current portion of long-term debt$3,300 $2,000 Accounts payable 1,982 2,156 Accrued expenses 12,491 8,486 Revenue share payable 2,591 5,053 Taxes payable — 318 Current portion of lease liabilities 209 168 Deferred revenue 484 473 Total current liabilities 21,057 18,654 Non-current liabilities Long-term debt, net 25,127 30,816 Lease liabilities, net of current portion 339 209 Deferred tax liabilities, net 3,458 4,491 Total liabilities 49,981 54,170 Stockholders’ equity Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at June 30, 2025 or December 31, 2024 — — Common stock, $0.001 par value, 166,666,667 shares authorized, 20,297,388 and 20,194,697 shares issued at June 30, 2025 and December 31, 2024, respectively 20 20 Treasury stock, $0.001 par value, 1,741,397 shares held at June 30, 2025 and December 31, 2024. (2) (2)Additional paid-in-capital 204,301 201,348 Accumulated deficit (85,035) (84,368)Total stockholders’ equity 119,284 116,998 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$169,265 $171,168 OPTIMIZERX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data, unaudited) For the Three Months EndedJune 30, For the Six Months EndedJune 30, 2025 2024 2025 2024 Net revenue$29,195 $18,812 $51,123 $38,502 Cost of revenues, exclusive of depreciation and amortization presented separately below 10,560 7,108 19,144 14,595 Gross profit 18,635 11,704 31,979 23,907 Operating expenses General and administrative expenses 14,372 14,380 28,736 30,545 Depreciation and amortization 1,074 1,073 2,168 2,140 Total operating expenses 15,446 15,453 30,904 32,685 Income (loss) from operations 3,189 (3,749) 1,075 (8,778)Other income (expense) Interest expense (1,603) (1,528) (2,899) (3,074)Other income 37 75 76 75 Interest income 90 106 177 125 Total other income (expense), net (1,476) (1,347) (2,646) (2,874)Income (loss) before provision for income taxes 1,713 (5,096) (1,571) (11,652)Income tax benefit (expense) (181) 1,088 904 744 Net income (loss)$1,532 $(4,008) $(667) $(10,908)Weighted average number of shares outstanding – basic 18,510,834 18,257,879 18,490,931 18,213,992 Weighted average number of shares outstanding – diluted 19,015,496 18,257,879 18,490,931 18,213,992 Income (loss) per share – basic$0.08 $(0.22) $(0.04) $(0.60)Income (loss) per share – diluted$0.08 $(0.22) $(0.04) $(0.60) OPTIMIZERX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands, unaudited) For the Six Months EndedJune 30, 2025 2024 OPERATING ACTIVITIES: Net loss$(667) $(10,908)Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation and amortization 2,168 2,140 Stock-based compensation 3,046 5,926 Bad debt expense — 132 Amortization of debt issuance costs 611 365 Changes in: Accounts receivable 4,700 11,600 Prepaid expenses and other assets (958) (1,457)Accounts payable (174) 752 Revenue share payable (2,462) (3,412)Accrued expenses and other liabilities 4,138 (2,264)Operating lease liabilities 9 — Deferred tax liabilities (1,033) — Taxes receivable and payable (964) (855)Deferred revenue 11 881 NET CASH PROVIDED BY OPERATING ACTIVITIES 8,425 2,900 INVESTING ACTIVITIES: Purchase of property and equipment (37) (77)Capitalized software development costs (91) (161)NET CASH USED IN INVESTING ACTIVITIES (128) (238) FINANCING ACTIVITIES: Cash paid for employee withholding taxes related to the vesting of restricted stock units (92) (555)Repayment of long-term debt (5,000) (1,000)NET CASH USED IN FINANCING ACTIVITIES (5,092) (1,555)NET INCREASE IN CASH AND CASH EQUIVALENTS 3,205 1,107 CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD 13,380 13,852 CASH AND CASH EQUIVALENTS - END OF PERIOD$16,585 $14,959 SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest$2,288 $2,710 Cash paid for income taxes$1,087 $110 OPTIMIZERX CORPORATIONRECONCILIATION of GAAP to NON-GAAP FINANCIAL MEASURES(in thousands, except share and per share data, unaudited) This earnings release includes certain financial measures not derived in accordance with generally accepted accounting principles (GAAP). These non-GAAP financial measures are measures of performance not defined by accounting principles generally accepted in the United States and should be considered in addition to, not in lieu of, GAAP reported measures. Additionally, these non-GAAP measures may not be comparable to similarly titled measures reported by other companies. However, management believes that presenting certain non-GAAP financial measures provides additional information to facilitate comparison of the Company's historical operating results and trends in its underlying operating results and provides transparency on how the Company evaluates its business. Management uses these non-GAAP financial measures in making financial, operating and planning decisions and in evaluating the Company's performance. Management believes that financial information excluding certain items that are not considered to reflect the Company’s ongoing operating results, such as those listed below, improves the comparability of year-to-year results. Consequently, management believes that investors may be able to better understand the Company’s operating results excluding these items. Non-GAAP financial measures may reflect adjustments for items such as asset impairment charges, amortization, stock-based compensation, acquisition expenses, severance, shareholder activist related fees, CEO search fees, other income, as well as other items that management believes are not related to the Company’s ongoing performance. For the Three Months EndedJune 30, For the Six Months EndedJune 30, 2025 2024 2025 2024Net income (loss)$1,532 $(4,008) $(667) $(10,908)Depreciation and amortization 1,074 1,073 2,168 2,140 Stock-based compensation 1,488 2,903 3,046 5,926 Severance expenses — 241 275 660 Shareholder activist related fees — — 451 — CEO search fees — — 225 — Other income (37) (75) (76) (75)Amortization of debt issuance costs 437 182 611 365 Acquisition expenses — — — 243 Non-GAAP net income (loss)$4,494 $316 $6,033 $(1,649) Non-GAAP net income (loss) per share Diluted$0.24 $0.02 $0.32 $(0.09)Weighted average shares outstanding: Diluted 19,015,496 18,358,543 18,599,906 18,213,922 For the Three Months EndedJune 30, For the Six Months EndedJune 30, 2025 2024 2025 2024Net income (loss)$1,532 $(4,008) $(667) $(10,908)Depreciation and amortization 1,074 1,073 2,168 2,140 Income tax (benefit) expense 181 (1,088) (904) (744)Stock-based compensation 1,488 2,903 3,046 5,926 Severance expenses — 241 275 660 Acquisition expenses — — — 243 Shareholder activist related fees — — 451 — CEO search fees — — 225 — Other income (37) (75) (76) (75)Interest expense, net 1,513 1,422 2,722 2,949 Adjusted EBITDA$5,751 $468 $7,240 $191

OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

FAQ

Why Bullish?

How important is it?

Why Short Term?

Related Companies

Related News